Previous 10 | Next 10 |
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS ® ) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector ® - - SCS Microinjector ® Feat...
ALPHARETTA, Ga., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Thomas A. Ciulla, M.D., MBA...
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Thomas A. Ciulla, M.D., MBA...
The following slide deck was published by Clearside Biomedical, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Clearside Biomedical, Inc. 2022 Q2 - Results - Earnings Call Presentation
Clearside Biomedical Inc (CLSD) Q2 2022 Earnings Conference Call August 09, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles De...
Clearside Biomedical press release ( NASDAQ: CLSD ): Q2 GAAP EPS of -$0.13 beats by $0.01 . Revenue of $0.38M (-51.3% Y/Y) beats by $0.08M . For further details see: Clearside Biomedical GAAP EPS of -$0.13 beats by $0.01, revenue of $0.38M beats by $0.08M...
- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call Today at 8:30...
ALPHARETTA, Ga., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today it has entered into a Royalty I...
Clearside Biomedical ( NASDAQ: CLSD ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estima...
Major earnings expected before the bell on Tuesday include: Bausch Health Companies ( BHC ) Cronos Group ( CRON ) Emerson Electric ( EMR ) Norwegian Cruise Line Holdings ( NCLH ) Workhorse Group ( WKHS ) For further details see: Notable ea...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...